





	Guo's sUbclavia	VeFlow-Tbranch™ : GUEST Study uo's state artgy recongrucțion: the prospective, multiple center study of WeFlow wranch™ stent graft system(GUEST Study). Clinical trial registry number:NCT04765605					
Primary safety en Freedom from N	ndpoint: IAE within 30 days a	after surgery: 95%	Immedi	effectiveness endpoint: ate technical success rate:99.1	, .,		
Primary safety en	dpoint events	n=120	107 pat	Primary Effectiveness End			
Rate of all-cause r	mortality (%)	0.83% (1)	Rate of in	mediate technical success, n=120	99.17% (119/120)	
Ischemic s	troke	2.50% (3)*		The Clinical Success Rate	12 Months	24 Months	
Respiratory Myocardial in		1.67% (2) 0 % (0)		Displacement of the stent graft	0%	0%	
Paraple	gia	0.83 % (1)	CTA	Displacement of thebranch stent graft	0%	0%	
Renal fai		0 % (0)		Type I and III endoleak	4.55% (5/110)	2.30% (2/87)	
Intestinal n		0 % (0) 0 % (0)		Branch stent occlusion	0.91% (1/110)	2.30% (2/87)	
Amputa Total		0 % (0) 5.00%		Secondary Intervention	4.17%	5.61- (6/107)	






PLAGH		WeFlow-Tribranch™ Results of First In Man Study			
Bas	eline characteristics:		Primary Endpoints:		
Baseline characteristics		N=17	MAE within 30 days	N=17	
Age		70.00 ± 10.12 (50~83)Y	All-cause Death	3/17 *	
	~~~	70.00 1 10.11 (30 03)1	Stroke	1/17	
	Male	76.47% (13)	Respiratory failure	1/17*	
	Hypertension	88.24% (15)	Pericardial tamponade	0	
	Hypertension		Dissection or aneurysm rupture	0	
Corona	ary Heart Disease History	11.76% (2)	Paraplegia	1/17	
	Diabetes		Stent occlusion	0	
	Diabetes	17.65% (3)	Stent fracture	0	
Cere	bral Infarction History	23.53% (4)	Stent displacement	0	
		82.35% (14)	Type I\III endoleak requiring treatment	0	
Туре	Arch aneurysms		Thrombosis or rupture of the approach vessel	• 1 5	
	Dissection	17.65% (3)	Conversion to open surgery	, Ę Þ)	







WeFlow-JAAATM: GREAT Study Great Stud								
WeFlow-JAAA [™] stent g								
rimary Safty Endpoint: 30 [	Day MAE (I	N=115)	Effi	Efficacy Endpoint Events				
All-cause Death	0.87% (	1) *	Immediate Technical Su	Immediate Technical Success [#] , n=115		99.13% (114/115)		
Myocardial Infarction	0% (0	))	Average Procedure T	Average Procedure Time, n=115				
Renal Failure	0% (0	1)	The Clinical Success Rate*	Post Procedure	6 Months	12 Months		
Respiratory Failure	0% (0	1)	Stent Migration (%)		0% (0/91)	0% (0/78)		
Ischemic Stroke	2.61% (	3) *	Type I or III Endoleak (%) *	1.79% (2/113)	0% (0/91)	0% (0/78)		
Bowel Ischemia	0% (0	)	Aneurysm Size Increase (%)	0% (0/113)	0% (0/91)	0% (0/78)		
Severe Ischemia Necrosis of Lower Limbs	0% (0	1)	Target vessel patency (%)	99.41% (336/338)	99.26% (270/272)	99.14% (231/233)		
Paraplegia	0% (0	3)	Secondary Intervention (%)	1.74%(2/115)	3.81% (4/105)	5.62%(5/89		
stient died of sudden cardiac arrest on postoperati stients experienced strokes during the perioperativ		est aneurysin related.	* During post-preceders, 6 months and 12 months ¹⁰ / ₂ The reducid failure reached from difficulty in came I small type I underlank and I type III moldone ware ¹⁰ / ₂ many sector and the sector right randomics of a collation of a 1 month, 1 for right randomics of a 5.	lating the eight renal vessels in 1 partie observed beliest decharge and both o	ave completed CTA exa at, and to right renal end	er could be place		

